Research programme: proto-oncogene-protein-c-bcl-2-inhibitors - AbbVie

Drug Profile

Research programme: proto-oncogene-protein-c-bcl-2-inhibitors - AbbVie

Alternative Names: A-371191; A-385358; ABT 737

Latest Information Update: 28 Mar 2014

Price : $50

At a glance

  • Originator Idun Pharmaceuticals
  • Developer Abbott Laboratories
  • Class Small molecules
  • Mechanism of Action Apoptosis stimulants; Proto-oncogene protein c-bcl-2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 28 Mar 2014 No development reported - Preclinical for Cancer in USA (unspecified route)
  • 02 Jan 2013 Abbott separates its pharmaceuticals business to new company called AbbVie
  • 21 Oct 2011 Preclinical trials in Cancer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top